20
Mar
2024
Clasp, Backed by Catalio, Third Rock & Novo, Gets $150M for Specific T-cell Engagers
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.